首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1888篇
  免费   105篇
  国内免费   11篇
耳鼻咽喉   18篇
儿科学   50篇
妇产科学   11篇
基础医学   111篇
口腔科学   48篇
临床医学   112篇
内科学   851篇
皮肤病学   14篇
神经病学   57篇
特种医学   62篇
外科学   308篇
综合类   14篇
一般理论   1篇
预防医学   59篇
眼科学   59篇
药学   149篇
中国医学   8篇
肿瘤学   72篇
  2024年   1篇
  2023年   14篇
  2022年   18篇
  2021年   80篇
  2020年   53篇
  2019年   78篇
  2018年   67篇
  2017年   52篇
  2016年   61篇
  2015年   58篇
  2014年   78篇
  2013年   102篇
  2012年   135篇
  2011年   151篇
  2010年   84篇
  2009年   93篇
  2008年   98篇
  2007年   127篇
  2006年   108篇
  2005年   104篇
  2004年   98篇
  2003年   71篇
  2002年   53篇
  2001年   33篇
  2000年   49篇
  1999年   26篇
  1998年   14篇
  1997年   8篇
  1996年   7篇
  1995年   6篇
  1994年   2篇
  1993年   4篇
  1992年   12篇
  1991年   13篇
  1990年   5篇
  1989年   6篇
  1988年   12篇
  1987年   6篇
  1986年   2篇
  1985年   3篇
  1984年   2篇
  1981年   2篇
  1978年   1篇
  1977年   1篇
  1973年   1篇
  1970年   1篇
  1969年   2篇
  1966年   1篇
  1962年   1篇
排序方式: 共有2004条查询结果,搜索用时 31 毫秒
81.

Background

Chronic renal failure is a progressive and irreversible loss of kidney function, and the hemodialysis (HD) is one of the most common modalities in this regard. Oxidative stresses [like interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α)] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients; meanwhile, antioxidants like alpha lipoic acid (ALA) may reduce the oxidative stress markers and the levels of inflammatory cytokines, so can improve of the patient’s quality of life.

Methods

In this randomized clinical trial study, 60 HD patients were randomly categorized in two case and control groups. Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks, and the control group received placebo capsules daily. The serum level of IL-8 and TNF-α was measured in both groups before and after the intervention.

Results

There were no significant differences in age, gender, duration of dialysis, and causative factor for dialysis between both groups (P > 0.05). The mean of IL-8 and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61, respectively; the difference between both groups was not statistically significant (P > 0.05).

Conclusion

Based on the better feeling and other beneficial effects of ALA were found in our study; we can conclude that it is a beneficial and recommended supplement, especially, for diabetic and dialysis patients.  相似文献   
82.

Background

A growing number of women with sporadic unilateral, early-stage breast cancers are undergoing ipsilateral therapeutic mastectomy with contralateral prophylactic mastectomy (CPM) to prevent the development of new cancers in the contralateral breast.

Methods

A decision-tree using TreeAge Pro 2012 software was used to model the costs and effects of CPM versus unilateral mastectomy (UM) in women younger than 50 years of age with sporadic unilateral, early stage breast cancers. Cost estimates were obtained from the Medicare Fee Schedule and the Healthcare Utilization Project. Probability estimates were obtained from the literature. Outcome effects were measured by incremental cost per quality-adjusted life year (QALY) gained. A 10-year risk period for contralateral breast cancer (CBC), a lifetime time horizon, and a societal perspective were used.

Results

Treatment with CPM results in 0.2 QALYs less than UM and $279 less in costs during a 10-year risk period and lifetime follow-up. The resulting incremental cost effectiveness ratio (ICER) is a savings of $1397 per QALY lost. The ICER is sensitive to the rate and method of postmastectomy reconstruction and the cost of radiologic surveillance after UM.

Conclusions

CPM is cost-saving for the prevention of CBC in women younger than 50 years of age with sporadic, unilateral, early-stage breast cancers, but also reduces resulting health. The savings for health lost are insufficient to be considered cost-effective at this time.  相似文献   
83.
Fracture characteristics were used to effectively evaluate the performance of fiber-reinforced cementitious composites. The fracture parameters provided the basis for crack stability analysis, service performance, safety evaluation, and protection. Much research has been carried out in the proposed study field over the previous two decades. Therefore, it was required to analyze the research trend from the available bibliometric data. In this study, the scientometric analysis and science mapping techniques were performed along with a comprehensive discussion to identify the relevant publication field, highly used keywords, most active authors, most cited articles, and regions with largest impact on the field of fracture properties of cement-based materials (CBMs). Furthermore, the characteristic of various fibers such as steel, polymeric, inorganic, and carbon fibers are discussed, and the factors affecting the fracture properties of fiber-reinforced CBMs (FRCBMs) are reviewed. In addition, future gaps are identified. The graphical representation based on the scientometric review could be helpful for research scholars from different countries in developing research cooperation, creating joint ventures, and exchanging innovative technologies and ideas.  相似文献   
84.
85.
86.
87.
88.
The prothrombin time (PT) represents the most commonly used coagulation test in clinical laboratories. The PT is mathematically converted to the international normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K antagonists such as warfarin in order to provide test results that are adjusted for thromboplastin and instrument used. The INR is created using two major PT ‘correction factors’, namely the mean normal PT (MNPT) and the international sensitivity index (ISI). Manufacturers of reagents and coagulometers have made some efforts to harmonizing INRs, for example, by tailoring reagents to specific coagulometers and provide associated ISI values. Thus, two types of ISIs may be generated, with one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer-specific ISI values. Although these play a crucial role in improving INR results between laboratories, these laboratories reported INR values are known to still differ, even when laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI values for a specific thromboplastin can vary among different models of coagulometers from a manufacturer using the same method for clot identification. All these factors can be sources of error for INR reporting, which in turn can significantly affect patient management. In this narrative review, we provide some guidance to appropriate ISI verification/validation, which may help decrease the variability in cross laboratory reporting of INRs.  相似文献   
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号